Analysis of Achalasia Treatment market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
The demand for achalasia treatment experienced a major rise in 2020 owing to the spread of Covid-19 crisis across the globe as the crisis created an emergent need to focus on health and well-being of people. In 2021, the well-recognized manufacturers are investing in research and development projects to come up with advanced next generation treatment procedures and drugs to ensure fastest recovery.
Prominent players including Aesculap Corporation, Silex Medical, Teva Pharmaceuticals, Bausch Health, Osmotica Pharmaceuticals PLC, Pfizer Incorporation and Mylan NV are focusing on the development of cost-effective and advanced treatments for ensuring fastest recovery rates among the patients suffering from achalasia. They are making investments in research and development activities to deliver innovation in medical facilities and procedures. For instance, Pzifer Corporation announced its latest introduction on 25th August, 2020 for treating patients suffering from achalasia. The drug is named ‘NCT00066716’ which is a combination of celecoxib, paclitaxel and carboplatin. Celecoxib may increase the effectiveness of chemotherapy drug by making tumor cells more sensitive to the drug and also stops the growth of tumor cells by stopping blood flow to the tumor and block the enzymes necessary for their growth. Combination of celecoxib with paclitaxel and carboplatin before surgery may shrink the tumor so that it can be removed during surgery. The drug is currently undergoing phase II trials to identify how well the combination works in treating patients who are undergoing surgeries for esophagal cancer. Pzifer has made the drug available across the world to expand its business and improve its global presence.
In addition to Pzifer Corporation, Sanofi Corporation announced that FDA has granted ‘Dupixent’ breakthrough therapy designation for eosinophilic esophagitis. Dupixent has become the first and only biologic to show positive and clinically meaningful phase 3 results in patients from 12 years and even older with eosinophilic esophagitis (EoE). There are currently no FDA approved treatments for the chronic type 2 inflammatory disease damaging esophagus except dupixent. Patients treated weekly with dupixent 300 mg over a 24-week treatment period experienced a reduction in symptoms, esophagal inflammation and abnormal endoscopic findings in the esophagus. The trial demonstrated safety results consistent with the known safety profile of dupixent in its approved indications. The EoE trial is ongoing with additional patients enrolling in part B as well as patients continuing in a 28-week extended active treatment period after completition of part A or part B. Breakthrough therapy is designed with the aim of expedeting the development and review of drugs that target serious conditions. Drugs qualifying for this designation must show preliminary clinical evidence that it may demonstrate a substantial endpoints over available therapies or over placebo if there are no available therapies. The potential use of dupixent in eosinophilic esophagitis is currently under clinical development.
Don't Need a Global Report?
Save 40% on Country & Region specific reports
Increasing number of patients in medical centers demanding for safe non-surgical treatments is expected to drive the demand for pneumatic dilation achalasia treatment. In addition, growing demand for fastest and simplest technique is likely to further drive the demand for pneumatic dilation achalasia treatment.
Low-risk and cost-effectiveness associated with pneumatic dilation is likely to offer growth opportunities for achalasia treatment market. Single session of the pneumatic dilation achalasia treatment is expected to provide relief for nearly seven years and follow up can be done as and when necessary. Women and older patients are witnessed as being majorly benefitted with pneumatic dilation achalasia treatment across the globe.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
The major factor driving the demand for POEM achalasia treatment is minimal patient discomfort and quicker recovery. In addition, POEM achalasia treatment helps in eliminating scars visibility, improves quality of life and moreover, eliminates the concern regarding hernias, which is likely to form at the laparoscopic incision sites.
Specialty clinics are likely to contribute on a major basis towards revenue growth of achalasia treatment market with increasing number of cases amongst children. Key players and manufacturers in achalasia treatment market are focusing on developing unmatched diagnostic tests with innovative treatments.
Across the globe, approximately 5% of the global population is suffering from a rare disorder, which makes the treatment of rare disorders a deliberating concern. Achalasia is a rare disorder of the oesophagus that is generally characterized by the incomplete relaxation of the lower oesophageal sphincter in response to swallowing.
The symptoms of achalasia include chest pain, weight loss, heartburn, regurgitation, nocturnal coughing, dysphagia and postprandial aspiration, among others. Dysphagia is the most common symptom in patients suffering from achalasia. The causes of achalasia are still unknown. Achalasia is associated with abnormalities of oesophageal peristalsis. Achalasia treatment involves the removal of obstructions caused because the lower oesophageal sphincter muscle fails to relax.
Drugs such as isosorbide or nifedipine can provide some relief to patients suffering from achalasia. It is estimated that approximately 70% of achalasia cases are more effectively treated by the enlargement of the lower oesophageal sphincter muscle through a procedure known as pneumatic balloon dilation. Achalasia generally affects adults aged between 25 and 60 years. However, it is likely to occur at any age, including childhood. The symptoms of achalasia appear gradually. People suffering from achalasia are expected to be at the risk of developing oesophageal cancer.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Increasing research grants and R&D expenditure form governments is driving the growth of the global achalasia treatment market. Rising government support is encouraging the development of treatment options for achalasia and are expected to change the landscape of achalasia treatment over the forecast period (2018-2028). Furthermore, the presence of a small number of affected people is likely to put a severe strain on the healthcare system. Rare disorders are supported by well-organized patient advocacy organizations such as National Organization for Rare Disorders (NORD).
However, inadequate treatment information about achalasia among healthcare providers is expected to restrain the global achalasia treatment market. In addition, awareness and understanding of rare disorders such as achalasia are often low and several patients are struggling to find adequate information about it. These factors are also expected to hamper the growth of the global achalasia treatment market.
Over the forecast period, achalasia treatment market is expected to witness moderate growth. Approximately 85-90% of achalasia cases can be treated with surgical procedures. During surgical procedures, the muscle fibres in the lower oesophageal sphincter are cut. Among surgical treatment types, the Heller Myotomy segment is expected to lead in the global achalasia treatment market over the forecast period. The hospitals end-user segment is expected to contribute to the maximum market share in the global achalasia treatment market. Achalasia treatment for patients majorly focuses on the improvement of symptoms.
Geographically, the global achalasia treatment market is segmented into North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). North America is expected to continue to dominate the global achalasia treatment market owing to the presence of prominent key players and favourable reimbursement scenario in the region.
The Asia Pacific achalasia treatment market is expected to grow at a maximum CAGR over the forecast period due to the entry of new players in the region and increasing awareness about achalasia treatment. The Middle East & Africa and Latin America regions are expected to hold a minimum market share in the global achalasia treatment market owing to lack of strategies for access to treatments for achalasia.
Some of the key players operating in the global achalasia treatment market are Allergan plc; Ipsen Biopharmaceuticals, Inc.; Nestlé Skin Health (Galderma S.A.); Merz Pharma; Aesculap, Inc. and Silex Medical, LLC.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global achalasia treatment market has been segmented on the basis of treatment, end user and geography.
Based on treatment, the global achalasia treatment market is segmented as:
Based on End User, the global achalasia treatment market is segmented as:
- Premium Report Details -
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunitiesPre Book
Get A Special pricing for start-ups and universitiesEnquiry Before Buying
- Humble, Yet Honored -
- Research Methodology -
An Adaptive Approach to Modern-day Research NeedsGet Methodology
The achalasia treatment market is likely to record a CAGR of 4.90% during the forecast period.
The achalasia treatment market has high growth potential due to technological advancements coupled with rising healthcare costs and growing awareness of disease symptoms.
The manufacturers of the achalasia treatment industry are likely to find the most opportunities in the North American region.
Need An Exclusive Report For Your Unique Requirement?